[Federal Register Volume 80, Number 41 (Tuesday, March 3, 2015)]
[Notices]
[Pages 11449-11454]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-04379]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-1721]


Agency Information Collection Activities; Submission for Office 
of Management and Budget Review; Comment Request; Investigational New 
Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that a 
proposed collection of information has been submitted to the Office of 
Management and Budget (OMB) for review and clearance under the 
Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by April 
2, 2015.

ADDRESSES: To ensure that comments on the information collection are 
received, OMB recommends that written comments be faxed to the Office 
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, 
FAX: 202-395-7285, or emailed to <a href="/cdn-cgi/l/email-protection#c3acaab1a29cb0b6a1aeaab0b0aaacad83acaea1eda6acb3eda4acb5"><span class="__cf_email__" data-cfemail="cfa0a6bdae90bcbaada2a6bcbca6a0a18fa0a2ade1aaa0bfe1a8a0b9">[email protected]</span></a>. All 
comments should be identified with the OMB control number 0910-0014. 
Also include the FDA docket number found in brackets in the heading of 
this document.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, 
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver 
Spring, MD 20993-0002, <a href="/cdn-cgi/l/email-protection#8fdfddcedcfbeee9e9cfe9ebeea1e7e7fca1e8e0f9"><span class="__cf_email__" data-cfemail="0c5c5e4d5f786d6a6a4c6a686d2264647f226b637a">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has 
submitted the following proposed collection of information to OMB for 
review and clearance.

Investigational New Drug (IND) Regulations--21 CFR Part 312 (OMB 
Control Number 0910-0014)--Extension

    FDA is requesting OMB approval for the reporting and recordkeeping 
requirements contained in FDA regulations entitled ``Investigational 
New Drug Application'' in part 312 (21 CFR part 312). Part 312 
implements provisions of section 505(i) of the Federal Food, Drug, and 
Cosmetic Act (the FD&C Act) (21 U.S.C. 355(i)) to issue regulations 
under which the clinical investigation of the safety and effectiveness 
of unapproved new drugs and biological products can be conducted.
    FDA is charged with implementing statutory requirements that drug 
products marketed in the United States be shown to be safe and 
effective, properly manufactured, and properly labeled for their 
intended uses. Section 505(a) of the FD&C Act provides that a new drug 
may not be introduced or delivered for introduction into interstate 
commerce in the United States unless FDA has previously approved a new 
drug application (NDA). FDA approves an NDA only if the sponsor of the 
application first demonstrates that the drug is safe and effective for 
the conditions prescribed, recommended, or suggested in the product's 
labeling. Proof must consist, in part, of adequate and well-controlled 
studies, including studies in humans, that are conducted by qualified 
experts. The IND regulations establish reporting requirements that 
include an initial application as well as amendments to that 
application, reports on significant revisions of clinical investigation 
plans, and information on a drug's safety or effectiveness. In 
addition, the sponsor is required to give FDA an annual summary of the 
previous year's clinical experience.
    Submissions are reviewed by medical officers and other Agency 
scientific reviewers assigned responsibility for overseeing the 
specific study. The IND regulations also contain recordkeeping 
requirements that pertain to the responsibilities of sponsors and 
investigators. The detail and complexity of these requirements are 
dictated by the scientific procedures and human subject safeguards that 
must be followed in the clinical tests of investigational new drugs.
    The IND information collection requirements provide the means by 
which FDA can monitor the clinical investigation of the safety and 
effectiveness of unapproved new drugs and biological products, 
including the following: (1) Monitor the safety of ongoing clinical 
investigations; (2) determine whether the clinical testing of a drug 
should be authorized; (3) ensure production of reliable data on the 
metabolism and pharmacological action of the drug in humans; (4) obtain 
timely information on adverse reactions to the drug; (5) obtain 
information on side effects associated with increasing doses; (6) 
obtain information on the drug's effectiveness; (7) ensure the design 
of well-controlled, scientifically valid studies; and (8) obtain other 
information pertinent to determining whether clinical testing should be 
continued, and information related to the protection of human subjects. 
Without the information provided by industry as required under the IND 
regulations, FDA cannot authorize or monitor the clinical 
investigations which must be conducted prior to authorizing the sale 
and general use of new drugs. These reports enable FDA to monitor a 
study's

[[Page 11450]]

progress, to assure subject safety, to assure that a study will be 
conducted ethically, and to increase the likelihood that the sponsor 
will conduct studies that will be useful in determining whether the 
drug should be marketed and available for use in medical practice.
    There are two forms that are required under part 312:
    Form FDA-1571--``Investigational New Drug Application.'' A person 
who intends to conduct a clinical investigation submits this form to 
FDA. It includes the following information:
    (1) A cover sheet containing background information on the sponsor 
and investigator;
    (2) A table of contents;
    (3) An introductory statement and general investigational plan;
    (4) An investigator's brochure describing the drug substance;
    (5) A protocol for each planned study;
    (6) Chemistry, manufacturing, and control information for each 
investigation;
    (7) Pharmacology and toxicology information for each investigation; 
and
    (8) Previous human experience with the investigational drug.
    Form FDA-1572--``Investigator Statement.'' Before permitting an 
investigator to begin participation in an investigation, the sponsor 
must obtain and record this form. It includes background information on 
the investigator and the investigation, and a general outline of the 
planned investigation and the study protocol.
    FDA is requesting OMB approval for the following reporting and 
recordkeeping requirements in part 312.

I. Reporting Requirements

Section 312.2(e)--Requests for FDA advice on the applicability of part 
312 to a planned clinical investigation.
Section 312.6--Labeling of an investigational new drug. Estimates for 
the information collection in this requirement are included under Sec.  
312.23(a)(7)(iv)(d).
Section 312.8--Charging for investigational drugs under an IND.
Section 312.10--Applications for waiver of requirements under part 312. 
As indicated in Sec.  312.10(a), estimates for the information 
collection in this requirement are included under Sec. Sec.  312.23 and 
312.31. In addition, other waiver requests under Sec.  312.10 are 
estimated in table 1.
Section 312.20(c)--Applications for investigations involving an 
exception from informed consent under Sec.  50.24 (21 CFR 50.24). 
Estimates for the information collection in this requirement are 
included under Sec.  312.23.
Section 312.23--IND (content and format).
Section 312.23(a)(1)--Cover sheet FDA-1571.
Section 312.23(a)(2)--Table of Contents.
Section 312.23(a)(3)--Investigational plan for each planned study.
Section 312.23(a)(5)--Investigator's brochure.
Section 312.23(a)(6)--Protocols--Phase 1, 2, and 3.
Section 312.23(a)(7)--Chemistry, manufacturing, and control 
information.
Section 312.23(a)(7)(iv)(a),(b),(c)--A description of the drug 
substance, a list of all components, and any placebo used.
Section 312.23(a)(7)(iv)(d)--Labeling: Copies of labels and labeling to 
be provided each investigator.
Section 312.23(a)(7)(iv)(e)--Environmental impact analysis regarding 
drug manufacturing and use.
Section 312.23(a)(8)--Pharmacological and toxicology information.
Section 312.23(a)(9)--Previous human experience with the 
investigational drug.
Section 312.23(a)(10)--Additional information.
Section 312.23(a)(11)--Relevant information.
Section 312.23(f)--Identification of exception from informed consent.
Section 312.30--Protocol amendments.
    Sec.  312.30(a)--New protocol
    Sec.  312.30(b)--Changes in protocol
    Sec.  312.30(c)--New investigator.
    Sec.  312.30(d)--Content and format.
    Sec.  312.30(e)--Frequency.
Section 312.31--Information amendments.
    Sec.  312.31(b)--Content and format.
    -- Chemistry, toxicology, or technical information.
Section 312.32--Safety reports.
    Sec.  312.32(c)(1)--Written reports to FDA and to investigators.
    Sec.  312.32(c)(2)--Telephone reports to FDA for fatal or life-
threatening experience.
    Sec.  312.32(c)(3)--Format or frequency.
    Sec.  312.32(d)--Followup submissions.
Section 312.33--Annual reports.
    Sec.  312.33(a)--Individual study information.
    Sec.  312.33(b)--Summary information.
    Sec.  312.33(b)(1)--Adverse experiences.
    Sec.  312.33(b)(2)--Safety report summary.
    Sec.  312.33(b)(3)--List of fatalities and causes of death.
    Sec.  312.33(b)(4)--List of discontinuing subjects.
    Sec.  312.33 (b)(5)--Drug action.
    Sec.  312.33 (b)(6)--Preclinical studies and findings.
    Sec.  312.33 (b)(7)--Significant changes.
    Sec.  312.33(c)--Next year general investigational plan.
    Sec.  312.33(d)--Brochure revision.
    Sec.  312.33(e)--Phase I protocol modifications.
    Sec.  312.33(f)--Foreign marketing developments.
Section 312.38(b) and (c)--Notification of withdrawal of an IND.
Section 312.41--Comment and advice on an IND. Estimates for the 
information collection in this requirement are included under Sec.  
312.23.
Section 312.42--Sponsor requests that a clinical hold be removed, and 
submits a complete response to the issues identified in the clinical 
hold order.
Section 312.44(c) and (d)--Opportunity for sponsor response to FDA when 
IND is terminated.
Section 312.45(a) and (b)--Sponsor request for, or response to, an 
inactive status determination of an IND.
Section 312.47--Meetings, including ``End-of-Phase 2'' meetings and 
``Pre-NDA'' meetings.
Section 312.48--Dispute resolution. Estimates for the information 
collection in this requirement are included under Sec.  312.47.
Section 312.53(c)--Investigator information. Investigator report (Form 
FDA-1572) and narrative; Investigator's background information; Phase 1 
outline of planned investigation and Phase 2 outline of study protocol.
Section 312.54(a) and (b)--Sponsor submissions concerning 
investigations involving an exception from informed consent under Sec.  
50.24.
    Sec.  312.55(b)--Sponsor reports to investigators on new 
observations, especially adverse reactions and safe use. Only ``new 
observations'' are estimated under this section; investigator brochures 
are included under Sec.  312.23.
Section 312.56(b), (c), and (d)--Sponsor monitoring of all clinical 
investigations, investigators, and drug safety; notification to FDA and 
others.
Section 312.58(a)--Sponsor's submission of records to FDA on request.
Section 312.64--Investigator reports to the sponsor.
    Sec.  312.64(a)--Progress reports.
    Sec.  312.64(b)--Safety reports
    Sec.  312.64(c)--Final reports.
    Sec.  312.64(d)--Financial disclosure

[[Page 11451]]

reports.
Section 312.66--Investigator reports to institutional review board 
(IRB). Estimates for the information collection in this requirement are 
included under Sec.  312.53.
Section 312.70--Investigator disqualification; opportunity to respond 
to FDA.
Section 312.83--Sponsor submission of treatment protocol. Estimates for 
this requirement are included under Sec.  312.320.
Section 312.85--Sponsors conducting phase 4 studies. Estimates for the 
information collection in this requirement are included under Sec.  
312.23, and under Sec. Sec.  314.50, 314.70, and 314.81 in OMB control 
number 0910-0001.
Section 312.110(b)--Requests to export an investigational drug.
Section 312.120--Submissions related to foreign clinical studies not 
conducted under an IND.
Section 312.130--Requests for disclosable information in an IND and 
from investigations involving an exception from informed consent under 
Sec.  50.24.
Sections 312.310(b); 312.305(b)--Submissions related to expanded access 
and treatment of an individual patient.
Section 312.310(d)--Submissions related to emergency use of an 
investigational new drug.
Sections 312.315(c); 312.305(b)--Submissions related to expanded access 
and treatment of an intermediate-size patient population.
Section 312.320--Submissions related to a treatment IND or treatment 
protocol.

II. Recordkeeping Requirements

Section 312.52(a)--Transfer of obligations to a contract research 
organization.
Section 312.57--Sponsor recordkeeping on the investigational drug.
Section 312.59--Sponsor recordkeeping of disposition of unused supply 
of drugs. Estimates for the information collection in this requirement 
are included under Sec.  312.57.
Section 312.62(a)--Investigator recordkeeping of disposition of drugs.
Section 312.62(b)--Investigator recordkeeping of case histories of 
individuals.
Section 312.120(d)--Recordkeeping requirements for submissions related 
to foreign clinical studies not conducted under an IND. Estimates for 
the information collection in this requirement are included under Sec.  
312.57.
Section 312.160(a)(3)--Records pertaining to the shipment of drugs for 
investigational use in laboratory research animals or in vitro tests.
Section 312.160(c)--Shipper records of alternative disposition of 
unused drugs.

    In the Federal Register of November 5, 2014 (79 FR 65663), FDA 
published a 60-day notice requesting public comment on the proposed 
collection of information. FDA received 24 comments, however, these 
comments did not address the information collection.
    FDA estimates the burden of this collection of information as 
follows:

                         Table 1--Estimated Annual Reporting Burden for Human Drugs \1\
----------------------------------------------------------------------------------------------------------------
                                                     Number of
         21 CFR section              Number of     responses per   Total annual   Average burden    Total hours
                                    respondents     respondent       responses     per response
----------------------------------------------------------------------------------------------------------------
312.2(e), Requests for FDA                   800            1                800              24          19,200
 advice on the applicability of
 part 312 to a planned clinical
 investigation..................
312.8, Requests to charge for an              56            1.25              70              48           3,360
 investigational drug...........
312.10, Requests to waive a                   50            1.76              88              24           2,112
 requirement in part 312........
312.23(a) through (f), IND                 1,689            1.57           2,648           1,600       4,236,800
 content and format (including
 Form FDA 1571).................
312.30(a) through (e), Protocol            3,739            5.77          21,588             284       6,130,992
 amendments.....................
312.31 (b), Information                    4,537            3.39          15,377             100       1,537,700
 amendments.....................
312.32(c) and (d), IND Safety                755           24.28          18,332              32         586,624
 reports........................
312.33(a) through (f), IND                 2,877            2.76           7,953             360       2,863,080
 Annual reports.................
312.38(b) and (c), Notifications             862            1.54           1,328              28          37,184
 of withdrawal of an IND........
312.42, Sponsor requests that a              158            1.30             205             284          58,220
 clinical hold be removed,
 including sponsor submission of
 a complete response to the
 issues identified in the
 clinical hold order............
312.44(c) and (d), Sponsor                    12            1                 12              16             192
 responses to FDA when IND is
 terminated.....................
312.45(a) and (b), Sponsor                   260            1.73             451              12           5,412
 requests for or responses to an
 inactive status determination
 of an IND by FDA...............
312.47, Meetings, including                  225            1.86             419             160          67,040
 ``End-of-Phase 2'' meetings and
 ``Pre-NDA'' meetings...........
312.53(c), Investigator reports            1,444            8.38          12,087              80         966,960
 submitted to the sponsor,
 including Form FDA 1572,
 curriculum vitae, clinical
 protocol, and financial
 disclosure. (Third party
 disclosure)....................
312.54(a), Sponsor submissions                 7            5                 35              48           1,680
 to FDA concerning
 investigations involving an
 exception from informed consent
 under 21 CFR 50.24.............
312.54(b), Sponsor notifications               7            1                  7              48             336
 to FDA and others concerning an
 IRB determination that it
 cannot approve research because
 it does not meet the criteria
 in the exception from informed
 consent in Sec.   50.24(a).
 (Includes third party
 disclosure)....................
312.55(a), Investigator                      590            3.50           2,067              48          99,216
 brochures submitted by the
 sponsor to each investigator.
 (Third party disclosure).......

[[Page 11452]]

 
312.55(b), Sponsor reports to                590            3.50           2,067              48          99,216
 investigators on new
 observations, especially
 adverse reactions and safe use.
 (Third party disclosure).......
312.56(b),(c), and (d), Sponsor            3,584            6.52          23,355              80       1,868,400
 notifications to FDA and others
 resulting from: (1) The
 sponsor's monitoring of all
 clinical investigations and
 determining that an
 investigator is not in
 compliance with the
 investigation agreements; (2)
 the sponsor's review and
 evaluation of the evidence
 relating to the safety and
 effectiveness of the
 investigational drug; and (3)
 the sponsor's determination
 that the investigational drug
 presents an unreasonable and
 significant risk to subjects.
 (Includes third party
 disclosure)....................
312.58(a), Sponsor's submissions              60            1                 60               8             480
 of clinical investigation
 records to FDA on request
 during FDA inspections.........
312.64, Investigator reports to            1,444            1              1,444              24          34,656
 the sponsor, including progress
 reports, safety reports, final
 reports, and financial
 disclosure reports. (Third
 party disclosure)..............
312.70, During the                             4            1                  4              40             160
 disqualification process of a
 clinical investigator by FDA,
 the number of investigator
 responses or requests to FDA
 following FDA's notification to
 an investigator of its failure
 to comply with investigation
 requirements...................
312.110(b)(4) and (b)(5),                     11           26.28             289              75          21,675
 Written certifications and
 written statements submitted to
 FDA relating to the export of
 an investigational drug........
312.120(b), Submissions to FDA             1,414            8.63          12,198              32         390,336
 of ``supporting information''
 related to the use of foreign
 clinical studies not conducted
 under an IND...................
312.120(c), Waiver requests                   35            2.34              82              24           1,968
 submitted to FDA related to the
 use of foreign clinical studies
 not conducted under an IND.....
312.130, Requests for                          3            1                  3               8              24
 disclosable information in an
 IND and for investigations
 involving an exception from
 informed consent under Sec.
 50.24..........................
312.310(b) and 312.305(b),                   228            1.76             401               8           3,208
 Submissions related to expanded
 access and treatment of an
 individual patient.............
312.310(d), Submissions related              410            2.19             899              16          14,384
 to emergency use of an
 investigational new drug.......
312.315(c) and 312.305(b),                    44            7.07             311             120          37,320
 Submissions related to expanded
 access and treatment of an
 intermediate-size patient
 population.....................
312.320(b), Submissions related               12           12.67             152             300          45,600
 to a treatment IND or treatment
 protocol.......................
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............      19,134,039
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.


                       Table 2--Estimated Annual Recordkeeping Burden for Human Drugs \1\
----------------------------------------------------------------------------------------------------------------
                                                     Number of                    Average burden
         21 CFR section              Number of      records per    Total annual         per         Total hours
                                   recordkeepers   recordkeeper       records      recordkeeping
----------------------------------------------------------------------------------------------------------------
312.52(a), Sponsor records for               335            1.50             503               2           1,006
 the transfer of obligations to
 a contract research
 organization...................
312.57, Sponsor recordkeeping              1,689            1              1,689             100         168,900
 showing the receipt, shipment,
 or other disposition of the
 investigational drug, and any
 financial interests............
312.62(a), Investigator                    1,444            1              1,444              40          57,760
 recordkeeping of the
 disposition of drugs...........
312.62(b), Investigator                    1,444            1              1,444              40          57,760
 recordkeeping of case histories
 of individuals.................
312.160(a)(3), Records                       547            1.40             782          * 0.50             391
 pertaining to the shipment of
 drugs for investigational use
 in laboratory research animals
 or in vitro tests..............
312.160(c), Shipper records of               547            1.40             782          * 0.50             391
 alternative disposition of
 unused drugs...................
                                 -------------------------------------------------------------------------------

[[Page 11453]]

 
    Total.......................  ..............  ..............  ..............  ..............         286,190
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.
* Thirty (30) minutes.


                          Table 3--Estimated Annual Reporting Burden for Biologics \1\
----------------------------------------------------------------------------------------------------------------
                                                     Number of
         21 CFR section              Number of     responses per   Total annual   Average burden    Total hours
                                    respondents     respondent       responses     per response
----------------------------------------------------------------------------------------------------------------
312.2(e), Requests for FDA                   217            1.18             255              24           6,120
 advice on the applicability of
 part 312 to a planned clinical
 investigation..................
312.8, Requests to charge for an              20            1.50              30              48           1,440
 investigational drug...........
312.10, Requests to waive a                    2            1                  2              24              48
 requirement in part 312........
312.23(a) through (f), IND                   335            1.35             452           1,600         723,200
 content and format.............
312.30(a) through (e), Protocol              694            5.84           4,050             284       1,150,200
 amendments.....................
312.31(b), Information                        77            2.43             187             100          18,700
 amendments.....................
312.32(c) and (d), IND Safety                161            8.83           1,421              32          45,472
 reports........................
312.33(a) through (f), IND                   745            2.14           1,595             360         574,200
 Annual reports.................
312.38(b) and (c), Notifications             134            1.69             227              28           6,356
 of withdrawal of an IND........
312.42, Sponsor requests that a               67            1.30              87             284          24,708
 clinical hold be removed,
 including sponsor submission of
 a complete response to the
 issues identified in the
 clinical hold order............
312.44(c) and (d), Sponsor                    34            1.15              39              16             624
 responses to FDA when IND is
 terminated.....................
312.45(a) and (b), Sponsor                    55            1.38              76              12             912
 requests for or responses to an
 inactive status determination
 of an IND by FDA...............
312.47, Meetings, including                   88            1.75             154             160          24,640
 ``End-of-Phase 2'' meetings and
 ``Pre-NDA'' meetings...........
312.53(c), Investigator reports              453            6.33           2,869              80         229,520
 submitted to the sponsor,
 including Form FDA-1572,
 curriculum vitae, clinical
 protocol, and financial
 disclosure.....................
312.54(a), Sponsor submissions                 1            1                  1              48              48
 to FDA concerning
 investigations involving an
 exception from informed consent
 under Sec.   50.24.............
312.54(b), Sponsor notifications               1            1                  1              48              48
 to FDA and others concerning an
 IRB determination that it
 cannot approve research because
 it does not meet the criteria
 in the exception from informed
 consent in Sec.   50.24(a).....
312.55(a), Number of                         239            1.91             457              48          21,936
 investigator brochures
 submitted by the sponsor to
 each investigator..............
312.55(b), Number of sponsor                 243            4.95           1,203              48          57,744
 reports to investigators on new
 observations, especially
 adverse reactions and safe use.
312.56(b), (c), and (d), Sponsor             108            2.21             239              80          19,120
 notifications to FDA and others
 resulting from: (1) The
 sponsor's monitoring of all
 clinical investigations and
 determining that an
 investigator is not in
 compliance with the
 investigation agreements; (2)
 the sponsor's review and
 evaluation of the evidence
 relating to the safety and
 effectiveness of the
 investigational drug; and (3)
 the sponsor's determination
 that the investigational drug
 presents an unreasonable and
 significant risk to subjects...
312.58(a), Number of sponsor's                 7            1                  7               8              56
 submissions of clinical
 investigation records to FDA on
 request during FDA inspections.
312.64, Number of investigator             2,728            3.82          10,411              24         249,864
 reports to the sponsor,
 including progress reports,
 safety reports, final reports,
 and financial disclosure
 reports........................
312.70, During the                             5            1                  5              40             200
 disqualification process of a
 clinical investigator by FDA,
 the number of investigator
 responses or requests to FDA
 following FDA's notification to
 an investigator of its failure
 to comply with investigation
 requirements...................
312.110(b)(4) and (b)(5), Number              18            1                 18              75           1,350
 of written certifications and
 written statements submitted to
 FDA relating to the export of
 an investigational drug........

[[Page 11454]]

 
312.120(b), Number of                        280            9.82           2,750              32          88,000
 submissions to FDA of
 ``supporting information''
 related to the use of foreign
 clinical studies not conducted
 under an IND...................
312.120(c), Number of waiver                   7            2.29              16              24             384
 requests submitted to FDA
 related to the use of foreign
 clinical studies not conducted
 under an IND...................
312.130, Number of requests for              350            1.34             470               8           3,760
 disclosable information in an
 IND and for investigations
 involving an exception from
 informed consent under Sec.
 50.24..........................
312.310(b) and 312.305(b),                    78            1.08              84               8             672
 Number of submissions related
 to expanded access and
 treatment of an individual
 patient........................
312.310(d), Number of                         76            2.76             210              16           3,360
 submissions related to
 emergency use of an
 investigational new drug.......
312.315(c) and 312.305(b),                     9            1                  9             120           1,080
 Number of submissions related
 to expanded access and
 treatment of an intermediate-
 size patient population........
312.320(b), Number of                          1            1                  1             300             300
 submissions related to a
 treatment IND or treatment
 protocol.......................
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............       3,254,062
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.


                        Table 4--Estimated Annual Recordkeeping Burden for Biologics \1\
----------------------------------------------------------------------------------------------------------------
                                                     Number of                    Average burden
         21 CFR section              Number of      records per    Total annual         per         Total hours
                                   recordkeepers   recordkeeper       records      recordkeeping
----------------------------------------------------------------------------------------------------------------
312.52(a), Sponsor records for                75            1.40             105               2             210
 the transfer of obligations to
 a contract research
 organization...................
312.57, Sponsor recordkeeping                335            2.70             904             100          90,400
 showing the receipt, shipment,
 or other disposition of the
 investigational drug, and any
 financial interests............
312.62(a), Investigator                      453            1                453              40          18,120
 recordkeeping of the
 disposition of drugs...........
312.62(b), Investigator                      453            1                453              40          18,120
 recordkeeping of case histories
 of individuals.................
312.160(a)(3), Records                       111            1.40             155          * 0.50              78
 pertaining to the shipment of
 drugs for investigational use
 in laboratory research animals
 or in vitro tests..............
312.160(c), Shipper records of               111            1.40             155          * 0.50              78
 alternative disposition of
 unused drugs...................
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............         127,006
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.
* Thirty (30) minutes.


    Dated: February 24, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-04379 Filed 3-2-15; 8:45 am]
BILLING CODE 4164-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>